Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Nearly one-third of families face catastrophic financial toxicity during pediatric ALL treatment, with significant household material hardship and income loss. Factors increasing HMH risk include ...

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

Teclistamab-cqyv plus subcutaneous daratumumab significantly improved OS and PFS in relapsed/refractory multiple myeloma compared to standard regimens, reducing death risk by 54%. The combination ...

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high ...

A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

The triplet regimen of azacitidine, venetoclax, and tagraxofusp showed high complete response rates in both untreated and relapsed/refractory BPDCN patients. Safety profile of the triplet was ...

The KOMET-007 trial demonstrated that ziftomenib combined with venetoclax and azacitidine was well-tolerated in relapsed/refractory AML patients with NPM1 mutations or KMT2A rearrangements. Common ...

MaaT013 showed a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits for responders. Safety profile was acceptable, with ...

Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...